Last reviewed · How we verify
NCT02446379: CLIO
Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery
trial testing The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose in Gastric Cancer. Withdrawn.
Quick facts
| Lead sponsor | Lightpoint Medical Limited |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Primary completion | 1 January 2016 |
| Sites | 1 location across Hungary |
Drugs / interventions tested
- The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose — full drug profile →
- EnLightTM
- LightPathTM Imaging System
Conditions studied
- Gastric Cancer — all drugs for Gastric Cancer →
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Bile Duct Cancer — all drugs for Bile Duct Cancer →
- Duodenal Cancer — all drugs for Duodenal Cancer →
Sponsor
Lightpoint Medical Limited — full company profile →
Who can join
30 and older, any sex, with Gastric Cancer or Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the performance of the EnLightTM and LightPathTM Imaging Systems in detecting tumour lesions in patients with gastric, pancreas, bile duct or duodenal cancer. EnLightTM will be used to detect positron emission and the LightPathTM system to detect Cerenkov Luminescence. Both are emitted by the Positron Emission Tomography (PET) agent. The study will also evaluate the patient safety and radiation safety of the EnLightTM, and the safety for the device operators and surgical staff of the LightPathTM Imaging System.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cerenkov luminescence imaging (CLI) for image-guided cancer surgery.
Grootendorst MR, Cariati M, Kothari A, Tuch DS, et al · · 2016 · cited 54× · PMID 27738626 · DOI 10.1007/s40336-016-0183-x
Verify or expand the search:
- PubMed search for NCT02446379
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer
Currently open trials in the same condition.
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02446379 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lightpoint Medical Limited
- Last refreshed: 26 January 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02446379.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing